A novel nanomedicine for osteosarcoma treatment: triggering ferroptosis through GSH depletion and inhibition for enhanced synergistic PDT/PTT therapy

Abstract Osteosarcoma treatment remains challenging due to the limitations of single-modality therapies. To address this, we designed a carrier-free nanomedicine SRF@CuSO4.5H2O@IR780 (CSIR) for synergistic ferroptosis, photodynamic therapy (PDT), and photothermal therapy (PTT) in osteosarcoma. Inter...

Full description

Saved in:
Bibliographic Details
Main Authors: Tangbing Xu, Qiming Ma, Chi Zhang, Xiaoyan He, Qian Wang, Yunfeng Wu, Kunpeng Qin, Faxue Liao, Ping Zhou, Pengfei Xu, Jialai Yang, Junjun Yang, Jun Chang, Lei Qiao, Yong Hu
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Journal of Nanobiotechnology
Subjects:
Online Access:https://doi.org/10.1186/s12951-025-03380-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849314663820427264
author Tangbing Xu
Qiming Ma
Chi Zhang
Xiaoyan He
Qian Wang
Yunfeng Wu
Kunpeng Qin
Faxue Liao
Ping Zhou
Pengfei Xu
Jialai Yang
Junjun Yang
Jun Chang
Lei Qiao
Yong Hu
author_facet Tangbing Xu
Qiming Ma
Chi Zhang
Xiaoyan He
Qian Wang
Yunfeng Wu
Kunpeng Qin
Faxue Liao
Ping Zhou
Pengfei Xu
Jialai Yang
Junjun Yang
Jun Chang
Lei Qiao
Yong Hu
author_sort Tangbing Xu
collection DOAJ
description Abstract Osteosarcoma treatment remains challenging due to the limitations of single-modality therapies. To address this, we designed a carrier-free nanomedicine SRF@CuSO4.5H2O@IR780 (CSIR) for synergistic ferroptosis, photodynamic therapy (PDT), and photothermal therapy (PTT) in osteosarcoma. Interestingly, CSIR could harness the enhanced permeability and retention (EPR) effect to effectively enter tumors. Copper ions (Cu2+) within CSIR could react with the reductive intracellular environment, depleting glutathione (GSH) levels. Near-infrared (NIR) irradiation of CSIR further depleted GSH through reactive oxygen species (ROS) generation. Additionally, CSIR released sorafenib (SRF), which inhibited cystine-glutamate antiporter system xCT (xCT), thereby blocking GSH biosynthesis. RNA sequencing data confirmed ferroptosis induction by CSIR. This synergistic strategy of GSH depletion-induced ferroptosis, enhanced PDT, and photothermal cascade holds promise for improved osteosarcoma treatment and future nanomedicine design.
format Article
id doaj-art-b0be5852ba6b4985b68e99b9d2eea70d
institution Kabale University
issn 1477-3155
language English
publishDate 2025-04-01
publisher BMC
record_format Article
series Journal of Nanobiotechnology
spelling doaj-art-b0be5852ba6b4985b68e99b9d2eea70d2025-08-20T03:52:24ZengBMCJournal of Nanobiotechnology1477-31552025-04-0123111710.1186/s12951-025-03380-4A novel nanomedicine for osteosarcoma treatment: triggering ferroptosis through GSH depletion and inhibition for enhanced synergistic PDT/PTT therapyTangbing Xu0Qiming Ma1Chi Zhang2Xiaoyan He3Qian Wang4Yunfeng Wu5Kunpeng Qin6Faxue Liao7Ping Zhou8Pengfei Xu9Jialai Yang10Junjun Yang11Jun Chang12Lei Qiao13Yong Hu14Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversitySchool of Life Sciences, Anhui Medical UniversityDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversityAnhui Public Health Clinical CenterDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Polymer Science and Engineering, University of Science and Technology of ChinaDepartment of Orthopaedics, The First Affiliated Hospital of Anhui Medical UniversityAbstract Osteosarcoma treatment remains challenging due to the limitations of single-modality therapies. To address this, we designed a carrier-free nanomedicine SRF@CuSO4.5H2O@IR780 (CSIR) for synergistic ferroptosis, photodynamic therapy (PDT), and photothermal therapy (PTT) in osteosarcoma. Interestingly, CSIR could harness the enhanced permeability and retention (EPR) effect to effectively enter tumors. Copper ions (Cu2+) within CSIR could react with the reductive intracellular environment, depleting glutathione (GSH) levels. Near-infrared (NIR) irradiation of CSIR further depleted GSH through reactive oxygen species (ROS) generation. Additionally, CSIR released sorafenib (SRF), which inhibited cystine-glutamate antiporter system xCT (xCT), thereby blocking GSH biosynthesis. RNA sequencing data confirmed ferroptosis induction by CSIR. This synergistic strategy of GSH depletion-induced ferroptosis, enhanced PDT, and photothermal cascade holds promise for improved osteosarcoma treatment and future nanomedicine design.https://doi.org/10.1186/s12951-025-03380-4Carrier-free nanomedicineOsteosarcomaFerroptosisPDT/PTT TherapyReactive oxygen species
spellingShingle Tangbing Xu
Qiming Ma
Chi Zhang
Xiaoyan He
Qian Wang
Yunfeng Wu
Kunpeng Qin
Faxue Liao
Ping Zhou
Pengfei Xu
Jialai Yang
Junjun Yang
Jun Chang
Lei Qiao
Yong Hu
A novel nanomedicine for osteosarcoma treatment: triggering ferroptosis through GSH depletion and inhibition for enhanced synergistic PDT/PTT therapy
Journal of Nanobiotechnology
Carrier-free nanomedicine
Osteosarcoma
Ferroptosis
PDT/PTT Therapy
Reactive oxygen species
title A novel nanomedicine for osteosarcoma treatment: triggering ferroptosis through GSH depletion and inhibition for enhanced synergistic PDT/PTT therapy
title_full A novel nanomedicine for osteosarcoma treatment: triggering ferroptosis through GSH depletion and inhibition for enhanced synergistic PDT/PTT therapy
title_fullStr A novel nanomedicine for osteosarcoma treatment: triggering ferroptosis through GSH depletion and inhibition for enhanced synergistic PDT/PTT therapy
title_full_unstemmed A novel nanomedicine for osteosarcoma treatment: triggering ferroptosis through GSH depletion and inhibition for enhanced synergistic PDT/PTT therapy
title_short A novel nanomedicine for osteosarcoma treatment: triggering ferroptosis through GSH depletion and inhibition for enhanced synergistic PDT/PTT therapy
title_sort novel nanomedicine for osteosarcoma treatment triggering ferroptosis through gsh depletion and inhibition for enhanced synergistic pdt ptt therapy
topic Carrier-free nanomedicine
Osteosarcoma
Ferroptosis
PDT/PTT Therapy
Reactive oxygen species
url https://doi.org/10.1186/s12951-025-03380-4
work_keys_str_mv AT tangbingxu anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT qimingma anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT chizhang anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT xiaoyanhe anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT qianwang anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT yunfengwu anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT kunpengqin anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT faxueliao anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT pingzhou anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT pengfeixu anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT jialaiyang anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT junjunyang anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT junchang anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT leiqiao anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT yonghu anovelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT tangbingxu novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT qimingma novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT chizhang novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT xiaoyanhe novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT qianwang novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT yunfengwu novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT kunpengqin novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT faxueliao novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT pingzhou novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT pengfeixu novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT jialaiyang novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT junjunyang novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT junchang novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT leiqiao novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy
AT yonghu novelnanomedicineforosteosarcomatreatmenttriggeringferroptosisthroughgshdepletionandinhibitionforenhancedsynergisticpdtptttherapy